Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: NEURONTIN
Published 2026-02-05 · Last reviewed 2026-02-12 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Gabapentin is an anticonvulsant/neuropathic pain medication (brand Neurontin) approved for adjunctive therapy in partial seizures and for postherpetic neuralgia (label). In psychiatric care it is sometimes used off label as a sedating adjunct for anxiety symptoms or sleep maintenance—particularly when clinicians are trying to avoid benzodiazepines or when comorbid pain is prominent.
Evidence for anxiety disorders is mixed. Gabapentin may help with physiologic hyperarousal and somatic tension in some patients, but it is not a first-line long-term treatment for generalized anxiety disorder, panic disorder, or PTSD compared with psychotherapy and SSRI/SNRI-based strategies.
The clinical “cost” is often sedation, dizziness, and gait instability. These effects can be substantial in older adults and in serious mental illness where polypharmacy and baseline neurologic impairment are common.
Gabapentin is not appreciably metabolized and is cleared renally as unchanged drug; renal function is the key determinant of safe dosing. When eGFR declines, dose accumulation can present as ataxia, confusion, and falls.
Misuse/diversion risk has increased in recent years. Treat escalating dose requests, lost prescriptions, or co-use with opioids/other sedatives as signals to reassess risk and to tighten prescribing controls.
The gabapentin compare view, gabapentin evidence feed, and gabapentin print page can support aligning anxiety/sleep adjuncts with sedation and misuse risk.
Because gabapentin is inexpensive and often perceived as “safer than benzos,” it can become a default PRN sedative without clear targets or follow-up. Use is often kept indication-specific (sleep maintenance, nocturnal anxiety, somatic tension, pain-related insomnia) and reassessed within weeks; sedation, falls, and misuse/diversion are monitored.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Binds the α2δ subunit of voltage-gated calcium channels, reducing calcium-dependent release of excitatory neurotransmitters. It does not directly bind GABA-A receptors despite the name.
Clinical “calming” effects likely reflect reduced hyperarousal and improved sleep continuity rather than direct anxiolysis; patients often describe less somatic tension and fewer nighttime awakenings.
Because the primary effect is sedating, response should be interpreted through a safety lens: if anxiety relief comes at the cost of daytime impairment or falls, alternative strategies are preferred.
Sources: FDA/DailyMed label; anxiety disorder review; misuse/diversion systematic reviews.